Inify Laboratories - mandatory notification of trade

27 Jan 2026 18:51 CET

Stockholm, Sweden, 27 January 2026; Inify Laboratories AB (publ.) (the
"Company") announces that the below primary insiders were allocated new shares
at the subscription price in the repair issue announced by the Company on 9
December 2025 (the "Repair Issue"), as further specified in the attached
notification forms:

-          Monsun AS, a company closely associated with board member Magne
Jordanger, has been allocated 898,204 Shares in the Repair Issue. Magne
Jordanger will, through the companies Monsun AS and Gallivant S.a.r.l. and
subject to completion of the Repair Issue and the Private Placement, own
76,868,249 shares in the Company.

-          Olof Sandén, chairman of the board, has been allocated 43,139 shares
in the Repair Issue. Sandén will, subject to the completion of the Repair Issue
own 159,979 shares in the Company.

-          Martin Ingvar, member of the board, has been allocated 67,132 shares
in the Repair Issue. Ingvar will, subject to the completion of the Repair Issue
own 283,195 shares in the Company.

-          Fredrik Palm, CEO of the Company, has been allocated 36,564 shares in
the Repair Issue. Palm will, subject to the completion of the Repair Issue own
139,613 shares in the Company.

-          Ann-Charlotte Linderoth, CFO of the Company, has been allocated
26,433 shares in the Repair Issue. Linderoth will, subject to the completion of
the Repair Issue own 99,433 shares in the Company.

For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com.

This information is subject to the disclosure requirements in the EU Market
Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian
Securities Trading Act.

###

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)

More information:
Access the news on Oslo Bors NewsWeb site

664304_Inify_Laboratories_PDMR_attachment.pdf